查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1572993

雙相情感障礙治療藥物市場：按治療藥物、作用機制、給藥途徑、患者年齡層、最終用戶和治療期分類 - 2025-2030 年全球預測

Bipolar Disorder Therapeutics Market by Therapeutics, Mechanism Of Action, Drug Administration Route, Patient Age Group, End User, Treatment Duration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年雙極性情感障礙治療藥物市值為60.1億美元，預計2024年將達到63.7億美元，複合年成長率為5.45%，預計到2030年將達到87.3億美元。

雙相情感障礙治療藥物市場的範圍包括旨在穩定雙相情感障礙相關情緒波動（例如躁狂、憂鬱症和混合發作）的藥物和治療的開發、生產和分銷。對創新性未滿足需求的需求在於，由於雙相情感障礙的複雜性，存在大量未滿足的醫療需求，影響著全世界數百萬人。應用包括情緒穩定劑、非典型抗精神病藥物和抗憂鬱症等藥物，以及神經調節和心理治療等新治療方法。最終用途主要包括醫療機構、精神病診所和研究機構，其驅動力是雙相情感障礙盛行率不斷上升、認知不斷提高以及全球醫療基礎設施的改善。

主要市場統計
基準年[2023] 60.1億美元
預測年份 [2024] 63.7億美元
預測年份 [2030] 87.3億美元
複合年成長率（%） 5.45%

影響市場成長的關鍵因素包括雙相情感障礙的盛行率不斷上升、增強個人化醫療的藥物基因組學的進步以及政府改善心理健康服務的舉措。然而，他們也面臨嚴格的監管要求、高昂的研發成本、潛在的藥物副作用以及與心理健康診斷和治療相關的社會恥辱等挑戰。儘管如此，透過增加研發投資、專注於精準醫療以及開發新型藥物輸送系統以改善治療效果，該市場提供了巨大的成長機會。公司可以利用這些優勢，與學術機構合作進行前沿研究，並擴大在醫療保健支出不斷增加的新興市場的影響力。

然而，市場參與企業必須應對一些限制，例如關鍵藥物的專利到期導致學名藥競爭以及全球市場監管一致性的需要。創新和研究可能會在探索聯合治療、先進診斷工具和支持治療依從性和監測的數位心理健康干預措施方面得到發展。市場動態是動態的，強調技術進步和綜合辦法。利用人工智慧和機器學習在護理管理中進行預測分析仍然是業務成長和策略洞察力的一個有前途的領域。

市場動態：快速發展的雙相情感障礙治療市場的關鍵市場洞察

雙極性情感障礙藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 新的數位健康技術能夠有效管理雙相情感障礙
    • 增加生物技術與藥物研發投入，推動雙極性情感疾患治療創新
    • 擴大醫療基礎設施和可近性，以改善雙相情感障礙患者的治療結果
    • 影響新雙相情感障礙藥物開發和核准的患者權益團體
  • 市場限制因素
    • 雙相情感障礙新療法的監管障礙和漫長的核准過程
    • 雙相情感障礙研究和開發的資金和投資不足影響創新
  • 市場機會
    • 擴大遠距精神病學服務，以提高雙相情感障礙患者獲得精神健康保健的機會
    • 將人工智慧融入雙相情感障礙診斷和治療計劃
    • 心理健康意識提升和教育工作，以減少與雙相情感障礙相關的恥辱
  • 市場挑戰
    • 人群對雙相情感障礙的認知和診斷有限阻礙了市場成長
    • 副作用的高發生率和患者對雙極性情感障礙藥物依從性差會影響治療結果。

波特的五力：駕馭雙極性情感障礙藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解雙極性情感疾患藥物市場的外在影響

外部宏觀環境因素在塑造雙極性情感障礙治療藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解雙極性情感疾患治療藥物市場的競爭狀況

雙極性情感障礙治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

雙極性情感障礙治療藥物市場供應商的 FPNV 定位矩陣績效評估

FPNV 定位矩陣是評估雙極性情感疾患治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為雙相情感障礙治療藥物市場的成功指明道路

對於旨在加強其在全球市場的影響力的公司來說，雙相情感障礙治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 新興的數位健康技術可以更有效地管理雙相情感障礙
      • 生物技術和藥物研發投資的增加推動雙相情感障礙治療的創新
      • 擴大醫療基礎設施和服務可改善雙相情感障礙患者的治療結果
      • 患者權益團體影響雙相情感障礙新藥的開發和核准
    • 抑制因素
      • 雙相情感障礙新療法的監管障礙和漫長的核准過程
      • 雙相情感障礙研究和開發的資金和投資不足影響創新
    • 機會
      • 擴大遠距精神病學服務，以提高雙相情感障礙患者獲得精神健康保健的機會
      • 將人工智慧融入雙相情感障礙診斷和治療計劃
      • 努力提高心理健康意識和教育，以減少與雙相情感障礙相關的恥辱
    • 任務
      • 公眾對雙相情感障礙的認知和診斷有限阻礙了市場成長
      • 雙極性情感障礙藥物副作用發生率高且患者依從性差會影響治療結果
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 雙極性情感疾患治療藥物市場治療

  • 抗驚厥藥
    • Carbamazepine
    • 拉莫三嗪
  • 抗憂鬱症
    • Fluoxetine
    • 帕羅西汀
    • 舍曲林
    • 文拉法辛
  • 抗精神病藥
    • Aripiprazole
    • Olanzapine
    • Quetiapine
    • Risperidone
  • 情緒穩定劑
    • 拉莫三嗪
    • 碳酸鋰
    • 丙戊酸

第7章雙極性情感疾患治療藥物市場（依作用機轉）

  • GABA促效劑
  • 麩胺酸促效劑
  • 離子通道阻斷劑
  • 單胺類藥物

第8章依藥品管理途徑分類的雙極性情感疾患治療藥物市場

  • 肌肉注射
  • 靜脈
  • 口服

第9章按患者年齡分類的雙相情感障礙治療藥物市場

  • 青春期
  • 成人用
  • 老年病
  • 小兒科

第 10 章 雙極性情感障礙治療藥物市場：依最終使用者分類

  • 家庭護理設置
  • 醫院
    • 住院病人
    • 門診病人
  • 專科診所
    • 情緒障礙診所
    • 精神科診所

第11章依治療時期分類的雙極性情感疾患治療藥物市場

  • 急性
  • 維護

第12章北美和南美雙相情感障礙治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太雙極性情感障礙治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲雙極性情感障礙治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0280

The Bipolar Disorder Therapeutics Market was valued at USD 6.01 billion in 2023, expected to reach USD 6.37 billion in 2024, and is projected to grow at a CAGR of 5.45%, to USD 8.73 billion by 2030.

The scope of the Bipolar Disorder Therapeutics market encompasses the development, production, and distribution of medications and treatments aimed at stabilizing mood swings associated with bipolar disorder, including manic, depressive, and mixed episodes. The necessity for innovative bipolar disorder therapeutics lies in the considerable unmet medical needs due to the disorder's complex nature, affecting millions worldwide. Applications cover pharmaceuticals like mood stabilizers, atypical antipsychotics, and antidepressants, alongside emerging therapies such as neuromodulation and psychotherapy. The end-use scope primarily involves healthcare institutions, psychiatric clinics, and research institutes, driven by an increasing prevalence of bipolar disorder, rising awareness, and improving healthcare infrastructure globally.

KEY MARKET STATISTICS
Base Year [2023] USD 6.01 billion
Estimated Year [2024] USD 6.37 billion
Forecast Year [2030] USD 8.73 billion
CAGR (%) 5.45%

Key factors influencing market growth include the growing incidence of bipolar disorder, advancements in pharmacogenomics enhancing personalized medicine, and government initiatives to improve mental health services. Conversely, the market faces challenges like stringent regulatory requirements, high R&D costs, potential side effects of drugs, and social stigma associated with mental health diagnosis and treatment. Nonetheless, the market presents significant growth opportunities through increased investment in R&D, focusing on precision medicine, and developing novel drug delivery systems to improve therapeutic outcomes. Companies can capitalize on these by collaborating with academic institutions for advanced research and expanding their presence in emerging markets with rising healthcare expenditure.

However, market players need to address limitations such as patent expirations of key drugs leading to generic competition, and the need for regulatory alignment across global markets. Innovation and research can thrive in areas exploring combination therapies, advanced diagnostic tools, and digital mental health interventions that support therapy adherence and monitoring. The nature of the bipolar disorder therapeutics market is dynamic, with an emphasis on technological advancements and comprehensive patient-centered approaches. Harnessing artificial intelligence and machine learning for predictive analytics in treatment management remains a promising area for business growth and strategic insight.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bipolar Disorder Therapeutics Market

The Bipolar Disorder Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Emerging digital health technologies enabling more efficient management of bipolar disorder
    • Growing investment in biotechnology and pharmaceutical R&D driving innovation in bipolar disorder treatments
    • Expansion of healthcare infrastructure and accessibility improving patient outcomes for bipolar disorder
    • Patient advocacy groups influencing the development and approval of new bipolar disorder medications
  • Market Restraints
    • Regulatory hurdles and lengthy approval processes for new bipolar disorder therapeutic drugs
    • Insufficient funding and investment in bipolar disorder research and development affecting innovation
  • Market Opportunities
    • Expansion of telepsychiatry services to enhance access to mental health care for bipolar disorder patients
    • Integration of artificial intelligence in diagnostics and treatment planning for bipolar disorder
    • Initiatives to increase mental health awareness and education to reduce stigma associated with bipolar disorder
  • Market Challenges
    • Limited awareness and diagnosis of bipolar disorder among the population hinders market growth
    • High prevalence of side effects and low patient adherence to bipolar disorder medications affect treatment outcomes

Porter's Five Forces: A Strategic Tool for Navigating the Bipolar Disorder Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bipolar Disorder Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bipolar Disorder Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bipolar Disorder Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bipolar Disorder Therapeutics Market

A detailed market share analysis in the Bipolar Disorder Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bipolar Disorder Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bipolar Disorder Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bipolar Disorder Therapeutics Market

A strategic analysis of the Bipolar Disorder Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bipolar Disorder Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes plc, Allergan plc, Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Mylan N.V., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Bipolar Disorder Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutics, market is studied across Anticonvulsants, Antidepressant Drugs, Antipsychotic Drugs, and Mood Stabilizers. The Anticonvulsants is further studied across Carbamazepine and Lamotrigine. The Antidepressant Drugs is further studied across Fluoxetine, Paroxetine, Sertraline, and Venlafaxine. The Antipsychotic Drugs is further studied across Aripiprazole, Olanzapine, Quetiapine, and Risperidone. The Mood Stabilizers is further studied across Lamotrigine, Lithium Carbonate, and Valproate Acid.
  • Based on Mechanism Of Action, market is studied across GABAergic Agents, Glutamatergic Agents, Ion Channel Blockers, and Monoaminergic Drugs.
  • Based on Drug Administration Route, market is studied across Intramuscular, Intravenous, and Oral.
  • Based on Patient Age Group, market is studied across Adolescent, Adult, Geriatric, and Pediatric.
  • Based on End User, market is studied across Homecare Settings, Hospitals, and Specialty Clinics. The Hospitals is further studied across Inpatient and Outpatient. The Specialty Clinics is further studied across Mood Disorder Clinics and Psychiatric Clinics.
  • Based on Treatment Duration, market is studied across Acute and Maintenance.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Emerging digital health technologies enabling more efficient management of bipolar disorder
      • 5.1.1.2. Growing investment in biotechnology and pharmaceutical R&D driving innovation in bipolar disorder treatments
      • 5.1.1.3. Expansion of healthcare infrastructure and accessibility improving patient outcomes for bipolar disorder
      • 5.1.1.4. Patient advocacy groups influencing the development and approval of new bipolar disorder medications
    • 5.1.2. Restraints
      • 5.1.2.1. Regulatory hurdles and lengthy approval processes for new bipolar disorder therapeutic drugs
      • 5.1.2.2. Insufficient funding and investment in bipolar disorder research and development affecting innovation
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of telepsychiatry services to enhance access to mental health care for bipolar disorder patients
      • 5.1.3.2. Integration of artificial intelligence in diagnostics and treatment planning for bipolar disorder
      • 5.1.3.3. Initiatives to increase mental health awareness and education to reduce stigma associated with bipolar disorder
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and diagnosis of bipolar disorder among the population hinders market growth
      • 5.1.4.2. High prevalence of side effects and low patient adherence to bipolar disorder medications affect treatment outcomes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bipolar Disorder Therapeutics Market, by Therapeutics

  • 6.1. Introduction
  • 6.2. Anticonvulsants
    • 6.2.1. Carbamazepine
    • 6.2.2. Lamotrigine
  • 6.3. Antidepressant Drugs
    • 6.3.1. Fluoxetine
    • 6.3.2. Paroxetine
    • 6.3.3. Sertraline
    • 6.3.4. Venlafaxine
  • 6.4. Antipsychotic Drugs
    • 6.4.1. Aripiprazole
    • 6.4.2. Olanzapine
    • 6.4.3. Quetiapine
    • 6.4.4. Risperidone
  • 6.5. Mood Stabilizers
    • 6.5.1. Lamotrigine
    • 6.5.2. Lithium Carbonate
    • 6.5.3. Valproate Acid

7. Bipolar Disorder Therapeutics Market, by Mechanism Of Action

  • 7.1. Introduction
  • 7.2. GABAergic Agents
  • 7.3. Glutamatergic Agents
  • 7.4. Ion Channel Blockers
  • 7.5. Monoaminergic Drugs

8. Bipolar Disorder Therapeutics Market, by Drug Administration Route

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intravenous
  • 8.4. Oral

9. Bipolar Disorder Therapeutics Market, by Patient Age Group

  • 9.1. Introduction
  • 9.2. Adolescent
  • 9.3. Adult
  • 9.4. Geriatric
  • 9.5. Pediatric

10. Bipolar Disorder Therapeutics Market, by End User

  • 10.1. Introduction
  • 10.2. Homecare Settings
  • 10.3. Hospitals
    • 10.3.1. Inpatient
    • 10.3.2. Outpatient
  • 10.4. Specialty Clinics
    • 10.4.1. Mood Disorder Clinics
    • 10.4.2. Psychiatric Clinics

11. Bipolar Disorder Therapeutics Market, by Treatment Duration

  • 11.1. Introduction
  • 11.2. Acute
  • 11.3. Maintenance

12. Americas Bipolar Disorder Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Bipolar Disorder Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Bipolar Disorder Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkermes plc
  • 3. Allergan plc
  • 4. Amgen Inc.
  • 5. AstraZeneca
  • 6. Bristol-Myers Squibb Company
  • 7. Eli Lilly and Company
  • 8. GlaxoSmithKline plc
  • 9. Johnson & Johnson
  • 10. Lundbeck A/S
  • 11. Merck & Co., Inc.
  • 12. Mylan N.V.
  • 13. Novartis AG
  • 14. Otsuka Pharmaceutical Co., Ltd.
  • 15. Pfizer Inc.
  • 16. Sanofi
  • 17. Sunovion Pharmaceuticals Inc.
  • 18. Supernus Pharmaceuticals, Inc.
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. BIPOLAR DISORDER THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. BIPOLAR DISORDER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. BIPOLAR DISORDER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIPOLAR DISORDER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIPOLAR DISORDER THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY QUETIAPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RISPERIDONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LITHIUM CARBONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VALPROATE ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GABAERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GLUTAMATERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ION CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MONOAMINERGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD DISORDER CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 274. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 286. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK BIPOLAR DISORDER THERAPEUTICS MARKET SIZ